The majority of Americans are in favor of using a newly approved vaccine to prevent human papillomavirus, according to The Wall Street Journal (8/8/2006). About 70% of Americans agree that girls and young women should be encouraged to receive the HPV vaccine to prevent the spread of cervical cancer, while 7% disagreed and 23% were not sure.
The majority of Americans are in favor of using a newly approved vaccine to prevent human papillomavirus, according to The Wall Street Journal (8/8/2006). About 70% of Americans agree that girls and young women should be encouraged to receive the HPV vaccine to prevent the spread of cervical cancer, while 7% disagreed and 23% were not sure.
The Food & Drug Administration approved the HPV vaccine (Gardasil) in June. It recommends that the vaccine be administered to girls and women ages 9 to 26, and notes that it is more effective before a woman becomes sexually active.
The Wall Street Journal Online/Harris Interactive Health-Care Poll is based on a nationwide online survey of 2,604 adults from July 27 to July 31. Among the other findings:
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More